Number | Relative risk | 95%CI lower limit | 95%CI upper limit | p value | |
---|---|---|---|---|---|
Acute GVHD (grades 2–4)a | |||||
Non-rituximab RIC | 1004 | 1 | 0.43 | ||
Rituximab-containing RIC | 377 | 1.14 | 0.83 | 1.56 | |
Acute GVHD (grades 3–4)a | |||||
Non-rituximab RIC | 1004 | 1 | 0.54 | ||
Rituximab-containing RIC | 377 | 1.16 | 0.72 | 1.89 | |
Chronic GVHD | |||||
Non-rituximab RIC | 982 | 1 | 0.22 | ||
Rituximab-containing RIC | 369 | 1.15 | 0.92 | 1.46 | |
Non-relapse mortality | |||||
Non-rituximab RIC | 988 | 1 | 0.51 | ||
Rituximab-containing RIC | 367 | 0.90 | 0.67 | 1.22 | |
Progression/relapse | |||||
Non-rituximab RIC | 988 | 1 | 0.055 | ||
Rituximab-containing RIC | 367 | 0.79 | 0.63 | 1.01 | |
PFS | |||||
Non-rituximab RIC | 988 | 1 | 0.006 | ||
Rituximab-containing RIC | 367 | 0.76 | 0.62 | 0.92 | |
Mortality | |||||
Non-rituximab RIC | 1022 | 1 | 0.08 | ||
Rituximab-containing RIC | 379 | 0.84 | 0.69 | 1.02 |